169 related articles for article (PubMed ID: 2685141)
1. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
Yaginuma Y; Yamashita K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
[TBL] [Abstract][Full Text] [Related]
2. ras oncogene product p21 expression and prognosis of human ovarian tumors.
Yaginuma Y; Yamashita K; Kuzumaki N; Fujita M; Shimizu T
Gynecol Oncol; 1992 Jul; 46(1):45-50. PubMed ID: 1634140
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.
Rodenburg CJ; Koelma IA; Nap M; Fleuren GJ
Arch Pathol Lab Med; 1988 Feb; 112(2):151-4. PubMed ID: 3276289
[TBL] [Abstract][Full Text] [Related]
5. Expression of the ras oncoprotein in gastric carcinomas and adjacent mucosa.
Karayiannis M; Yiagnisis M; Papadimitriou K; Spandidos DA
Anticancer Res; 1989; 9(6):1505-10. PubMed ID: 2697179
[TBL] [Abstract][Full Text] [Related]
6. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical study of ras p21 expression in human gastric cancers and benign lesions].
Nakajima K
Hokkaido Igaku Zasshi; 1987 Jul; 62(4):573-80. PubMed ID: 3315926
[TBL] [Abstract][Full Text] [Related]
9. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
10. Identification of LDH-ras p21 protein complex and expression of these genes in human ovarian cancer.
Chow SN; Lin JK; Li SS; Chien CH
Gynecol Oncol; 1997 Jan; 64(1):114-20. PubMed ID: 8995558
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemical studies of ras oncogene product p21 in 7,12 dimethylbenz (a) anthracene-induced rat ovarian tumors].
Kataoka A; Hirakawa N; Sugiyama T; Higashijima T; Nishida T; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Sep; 43(9):1209-13. PubMed ID: 1919181
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
[TBL] [Abstract][Full Text] [Related]
15. [Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer].
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Ueno Y; Yamashita H; Nomura K; Ichiguchi O
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2271-5. PubMed ID: 1656890
[TBL] [Abstract][Full Text] [Related]
16. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
17. Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis.
Viel A; Dall'Agnese L; Canzonieri V; Sopracordevole F; Capozzi E; Carbone A; Visentin MC; Boiocchi M
Cancer Res; 1995 Jun; 55(12):2645-50. PubMed ID: 7780979
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.
Miao TJ; Wang Z; Sang N
Eur Urol; 1991; 20(4):307-10. PubMed ID: 1814747
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of the ras oncogene expression in human bladder endoscopy specimens.
Agnantis NJ; Constantinidou A; Poulios C; Pintzas A; Kakkanas A; Spandidos DA
Eur J Surg Oncol; 1990 Apr; 16(2):153-60. PubMed ID: 2182341
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
